<DOC>
	<DOCNO>NCT00160316</DOCNO>
	<brief_summary>The purpose study demonstrate endometrial safety continuous combine 0.5 mg estradiol 2.5 mg dydrogesterone .</brief_summary>
	<brief_title>Endometrial Safety Study 0.5 mg Estradiol 2.5 mg Dydrogesterone Combination</brief_title>
	<detailed_description />
	<mesh_term>Dydrogesterone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Amenorrhoea &gt; = 12 month . Serum estradiol FSH level within postmenopausal range Baseline endometrial biopsy assess light microscopic histological evaluation revealing : insufficient endometrial tissue diagnosis insufficient available ( atrophic ) endometrial tissue ( inaccessible cervix ) endometrial thickness &lt; 5 mm ( double layer ) transvaginal ultrasound , atrophic endometrium , secretory endometrium , menstrual type endometrium , proliferative endometrium Previous systemic unopposed estrogen replacement therapy 6 month . Any estrogen , progestogen , and/or androgen therapy last four week Screening Visit ( Visit 1 ) . The baseline endometrial biopsy case take cessation withdrawal bleed due previous hormone replacement therapy . History presence estrogen dependent neoplasia ( include breast cancer ) . History presence malignant neoplasms basal spinal cell carcinoma skin .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>